Cytokinetics Inc [CYTK] stock is trading at $57.38, down -0.07%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CYTK shares have gain 1.09% over the last week, with a monthly amount glided 7.21%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Cytokinetics Inc [NASDAQ: CYTK] stock has seen the most recent analyst activity on January 24, 2024, when UBS downgraded its rating to a Neutral and also boosted its price target to $92 from $61. Previously, Morgan Stanley downgraded its rating to Equal-Weight on January 05, 2024, and elevated its price target to $90. On November 09, 2023, Goldman initiated with a Buy rating and assigned a price target of $50 on the stock. B. Riley Securities started tracking the stock assigning a Buy rating and suggested a price target of $66 on November 07, 2023. SVB Securities initiated its recommendation with a Outperform and recommended $58 as its price target on August 15, 2023. BofA Securities started tracking with a Neutral rating for this stock on February 17, 2023, and assigned it a price target of $49. In a note dated December 23, 2022, Needham reiterated an Buy rating on this stock and revised its target price from $60 to $58.
Cytokinetics Inc [CYTK] stock has fluctuated between $25.98 and $110.25 over the past year. Currently, Wall Street analysts expect the stock to reach $82.67 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $57.38 at the most recent close of the market. An investor can expect a potential return of 44.07% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
Cytokinetics Inc [NASDAQ:CYTK] reported sales of 3.75M for the trailing twelve months, which represents a drop of -81.90%. Gross Profit Margin for this corporation currently stands at -45.48% with Operating Profit Margin at -132.72%, Pretax Profit Margin comes in at -141.42%, and Net Profit Margin reading is -141.42%. To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is 1.37 and Total Capital is -0.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.61.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 56.33 points at the first support level, and at 55.27 for the second support level. However, for the 1st resistance point, the stock is sitting at 58.32, and for the 2nd resistance point, it is at 59.25.
Ratios To Look Out For
For context, Cytokinetics Inc’s Current Ratio is 7.19. Also, the Quick Ratio is 7.19, while the Cash Ratio stands at 1.35. Considering the valuation of this stock, the price to sales ratio is 1754.45.
Transactions by insiders
Recent insider trading involved Malik Fady Ibraham, EVP Research & Development, that happened on Jul 23 ’24 when 7300.0 shares were sold. Director, PARSHALL B LYNNE completed a deal on Jul 15 ’24 to sell 5000.0 shares. Meanwhile, President & CEO Blum Robert I sold 11500.0 shares on Jul 10 ’24.
